Microfibril-associated glycoprotein-1 (MAGP1) is found associated with microfibrils in the extracellular matrix (ECM). In humans, MAGP1 is expressed as two alternatively spliced isoforms: MAGP1A, the extracellular microfibril-associated form; and MAGP1B, an exclusively intracellular isoform derived from the skipping of exon 3. The biological function of MAGP1B is unknown. We performed gene expression profiling to study the cellular response to MAGP1B using whole-genome genechips. We found that MAGP1B specifically induces the expression of genes linked to cell adhesion, motility, metabolism, gene expression, development and signal transduction. Versican, a gene product involved in the structure and functional regulation of the ECM, showed the highest up-regulation in response to MAGP1B. These studies suggest a dual role for MAGP1, with extracellular MAGP1A involved in ECM function, and intracellular MAGP1B modulating the expression of genes that function in cell adhesion, migration and control of ECM deposition.
Introduction
Microfibrils are ubiquitous structures in the extracellular matrix (ECM) of most tissues, particularly elastic tissues, bone, and cartilage (Mecham & Davis, 1994) . Microfibrils make an essential contribution to the structural integrity of tissues, anchor cells to matrix components through cell adhesion motifs (Robinson & Godfrey, 2000) , sequester growth factors in the ECM (Charbonneau, Ono, Corson, Keene, & Sakai, 2004) , and signal cells by interacting with cell-surface receptors (Sakamoto et al., 1996) . Microfibril-associated glycoproteins (MAGPs) are low molecular weight components of the microfibrils (Gibson, Sandberg, Grosso, & Cleary, 1991) . MAGP1 is a 183-amino acid protein with two domains: an amino terminal half enriched in proline and glutamine residues; and a carboxy terminal half with a 54-amino acid region that targets MAGP1 to the ECM (Segade, Trask, Broekelmann, Pierce, & Mecham, 2002) . Extracellular MAGP1 is known to bind to tropoelastin, collagen VI, fibrillin, decorin, and biglycan (Brown-Augsburger et al., 1994; Finnis & Gibson, 1997; Reinboth, Hanssen, Cleary, & Gibson, 2002; Trask, Trask, Broekelmann, & Mecham, 2000; Werneck et al., 2004) . MAGP1 interacts with and facilitates the shedding of Notch (Miyamoto, Lau, Hein, Shipley, & Weinmaster, 2006) .
MAGP1 is encoded by the Mfap2 (from microfibrilassociated protein 2) gene located in chromosome 1p31 in human (Faraco, Bashir, Rosenbloom, & Francke, 1995) and 4qD3 in mouse (Chen et al., 1993) . Ortholog sequences are present in amphibians and teleost fishes (Segade et al., 2002) . In mammals the gene is split in 9 exons of which exon 1 is non-coding. Analysis of the human gene expression databases (Karolchik et al., 2003) shows that MAGP1 mRNA expression is highest in blood vessels, lung, and placenta and, in general terms, in organs rich in smooth muscle (e.g. uterus, prostate) .
Canonical splicing of the human MAGP1 pre-mRNA gives rise to a 1.3-kb transcript. Alternative splicing originates species-specific splice variants of MAGP1 (Segade, Broekelmann, Pierce, & Mecham, 2000) . In humans, the alternate MAGP1B mRNA originates from an exon-skipping event that prevents the incorporation of exon 3 into the processed transcript. The MAGP1B transcript is present in normal tissue RNA with differential expression patterns (Segade et al., 2000) . Interestingly, MAGP1B message was found in cells that do not deposit an ECM, like peripheral leukocytes, suggesting that MAGP1 could possess a second biological role independent from its function in the ECM. The skipped exon codes for 30 amino acids that include a portion of the signal peptide including the cleavage site, indicative of an intracellular location (Segade et al., 2000) . This hypothesis was later verified by the observation that a GFP-tagged MAGP1B accumulates in the cytoplasm and is not secreted (Segade et al., 2002) .
In order to define the intracellular role of MAGP1B we performed a transcriptome analysis of the cellular response to MAGP1B. As sources of RNA for microarray analysis we developed stably transfected human cell lines expressing each of the human MAGP1 alternate isoforms. We found that MAGP1B modulates a unique set of genes that suggest a role of MAGP1B in cell processes that involve cell migration, adhesion and control of ECM deposition.
Materials and methods

Cell culture
The human osteosarcoma cell line SAOS-2 (ATCC HTB-85) (Fogh, Fogh, & Orfeo, 1977) was purchased from the American Type Culture Collection and routinely maintained in Dulbecco's modified Eagle's medium (DMEM, Cambrex) supplemented with 10% fetal bovine serum (Invitrogen), 10 units/ml of penicillin, and 10 g/ml of streptomycin. Cells were cultured in a standard humidified incubator at 37 • C in a 5% CO 2 -95% O 2 atmosphere.
Recombinant plasmids
Construction of the chimeric MAGP-V5-6His fusion proteins was carried out in the pcDNA3.1/V5-His plasmid (Invitrogen). Genes cloned into this vector are expressed under the control of the CMV promoter. The MAGP1A-V5 vector with the full length (183 amino acids) human MAGP1A was constructed by amplification using the forward HM-5 (5 -TTAGAATTCGCCA-TGAGAGCTGCCTAC-3 ) and reverse HM-3 (5 -TTATCTAGAGCAGCTCCCACAGCTCCT-3 ) primers and human MAGP1A cDNA (Segade et al., 2000) as a template to generate a 560-bp amplification product. The MAGP1B-V5 plasmid containing the human MAGP1B coding sequence (153 amino acids) was constructed by amplification with the HM-5 and HM-3 primers using the human EST clone H27217 template (Genome Systems) to generate a 470-bp amplification product. PCR fragments were gel-purified, and digested with EcoRI and XbaI for ligation to pcDNA3.1/V5-His. The integrity of the constructs was verified by sequencing with the T7 and BGH primers (Invitrogen) and analyzed with Chromas software. Plasmids were routinely purified from bacterial cultures with the Qiagen EndoFree Maxi DNA purification kit.
Generation of MAGP1 stable transfectants in SAOS-2 cells
SAOS-2 cells at ∼90% confluence were transfected with 5 g of the appropriate plasmid using 5 l of the LipofectAMINE 2000 (Invitrogen) transfection reagent for 6 h. Transfectants were selected by culture in growth medium supplemented with 700 g/ml of Geneticin (Invitrogen) for 17 days. Geneticin-resistant cells were pooled and RNA was extracted to verify the expression of the appropriate MAGP1 transgene mRNA by conventional RT-PCR.
RNA isolation
Total RNA was extracted from SAOS-2 stable transfectants using the isothiocyanate-acid phenol method (Chomczynski & Sacchi, 1987) , and further purified by chromatography using the Qiagen RNeasy system according to the manufacturer's instructions. The integrity of the RNA was ascertained by electrophoretic separation of 2 g of total RNA in 1.2% agarose-formaldehyde denaturing gels and visualized by ethidium bromide staining.
cDNA synthesis and conventional PCR analysis
Single-stranded cDNA was synthesized from 1 g of total RNA in a final volume of 20 l containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 5 mM MgCl 2 , 500 M dNTP mix, 50 g random hexamers and 200 units of Super Script III Reverse Transcriptase (Invitrogen) at 50 • C for 50 min followed by inactivation of the reverse transcriptase at 70 • C for 10 min and hydrolysis of the template RNA with 2 units of RNase H (Invitrogen) at 37 • C for 30 min. After digestion with 2 units of RNase H, 1 g of cDNA was used as template for PCR. mRNA samples incubated in the absence of reverse transcriptase served as negative controls. For conventional PCR, the cDNA equivalent of 200 ng of total SAOS-2 RNA was amplified with 0.4 M each of the appropriate primers (Table 1 ) in a 25-l volume containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl 2 , 200 M dNTP mix, and 2 units of Titanium Taq DNA polymerase (Clontech). After an initial denaturation at 95 • C for 1 min, 30 cycles of amplification were performed at 95 • C for 30 s, 60 • C for 30 s and 68 • C for 30 s, followed by 3 min at 68 • C as an additional extension step. PCR products were then separated in 2% agarose gels and visualized by ethidium bromide staining.
Indirect immunofluorescence
For indirect immunofluorescence detection, cultures of SAOS-2 cells, plated on microscopy coverslips, were washed with phosphate-buffered saline and fixed with cold methanol. Non-specific immunoreactivity was blocked with 1% fat-free milk in phosphate-buffered saline for 1 h at room temperature. Coverslips were then incubated with monoclonal anti-V5 primary antibody (Invitrogen) for 1 h at room temperature, followed by several washes in blocking solution and a second incubation with Alexa 488-conjugated goat anti-mouse secondary antibody (Santa Cruz Biotechnology) for 30 min. Slides were washed and mounted on microarray slides. Fluorescence was examined with a Leitz DM-RBE fluorescence microscope equipped with a single-channel CCD camera. Images acquired with 10-40× objectives and a 10× eyepiece were recorded and manipulated using Openlab 3.5.1 software.
Microarray hybridization experiments
Total RNA was purified from SAOS-2 transfectants as described above. RNA labeling and hybridization were carried out at the Wake Forest University Affymetrix Microarray Core Facility according to the recommended protocols. Briefly, biotin-labeled RNA was hybridized to Affymetrix Human Genome U133A probe arrays, stained with streptavidin-PE conjugate (Molecular Probes), and the fluorescence intensities were measured with an Affymetrix GeneScanner laser confocal scanner, according to the manufacturer's instructions. Two independent transfection-hybridization experiments were performed for each expression vector.
Statistical analysis of the hybridization data
Raw data from the hybridization experiments was processed using the Affymetrix Microarray Suite Ver- 
Quantitative real-time PCR
Results from the microarray analysis were validated by quantitative real-time PCR. PCR primer sequences for target genes were designed from mRNA sequences deposited in Genbank with PrimerBank (http://pga.mgh.harvard.edu/primerbank/index.html) (Wang & Seed, 2003) . Primers were designed for products in the 150-200 bp range, preferentially from sequence closer to the 5 -end of each gene, and with forward and reverse primers on different exons (Table 1) . PCR conditions were checked and optimized using a range of annealing temperatures. Real-time quantitative RT-PCR was carried out in 96-well plates using an ABI PRISM 7000 Sequence Detection System. Total RNA extracted from stably transfected SAOS-2 cells and purified through RNeasy columns was treated with RNase-free DNase (Promega) to avoid spurious amplification from copurifying genomic DNA. First-strand cDNA was synthesized from 1 g of total RNA with 2.5 M random hexamers as primers and 60 units of Multiscribe reverse transcriptase (Applied Biosystems). The reaction (50 l) was incubated at 25 • C for 10 min, followed by incubation at 48 • C for 30 min and 95 • C for 5 min. cDNA were used as template for quantitative real-time PCR with the SYBR green chemistry detection method. Amplification mixtures totaling 50 l per reaction contained 4 l of template, 1× SYBR Premix Ex Taq master mix buffer (Takara Mirus Bio), 1× ROX passive reference dye, and 0.2 M forward and reverse primers. Cycling conditions followed the manufacturer's recommendations for a three-step PCR protocol with a 10-s initial denaturation at 95 • C followed by 40 cycles at 95 • C for 5 s, 55-60 • C for 20 s and 72 • C for 30 s, with quantification detection at the 72 • C extension step. A final quantified denaturing step from 55 to 95 • C produced a melting curve to determine product specificity. Universal 18S rRNA endogenous control primers and probe sets were purchased from Applied Biosystems. All samples were run in triplicate, with a no-template negative control. Levels of mRNA were calculated from the threshold cycle number (C t ) during the exponential phase of the PCR amplification. The C t was established as the cycle number at which the amount of amplified target reached a fixed fluorescence threshold. The mean (±S.E.M.) C t values of the experimental triplicates were calculated for each gene and sample. Samples with more than 10% of variation within the triplicate were retested or excluded. The difference between the C t values of the target gene and the endogenous control was determined to calculate C t = C t(target gene) − C t(reference) . For each target gene, normalization was performed against the values in the SAOS-C line, with each SAOS-C C t value subtracted from the C t in SAOS-MAGP1A or SAOS-MAGP1B to obtain the C t (Livak & Schmittgen, 2001 ). Finally, the relative expression R of each target gene in the SAOS-MAGP1A or SAOS-MAGP1B lines was calculated as R = 2 − C t . The statistical significance of differences in expression levels was determined with the multiple t-test. The significance level was defined as p < 0.05.
Results
Characterization of MAGP1A and MAGP1B stable transfectants in SAOS-2 cells
To generate stable transfectants in the human SAOS-2 osteosarcoma cell line, MAGP1A or MAGP1B coding sequences were subcloned into the pcDNA3.1/V5-6His vector. Empty pcDNA3.1/V5-6His vector was used to generate the negative control cell line SAOS-C. Expression of the splice form-specific mRNAs from G418-resistant clones was ascertained by conventional RT-PCR using primers derived from exons 2 (HM5) and 6 (HM3) of the human gene. As shown in Fig. 1A , a 336-bp amplification product was obtained from the SAOS-MAGP1A cell line which, upon sequencing, was confirmed to correspond to the MAGP1A sequence. Similarly, RT-PCR using SAOS-MAGP1B RNA produced a 246-bp amplification product that corresponds to the exon 3-skipped MAGP1B (Fig. 1A) . Relative levels of MAGP1A and MAGP1B were assessed by realtime PCR (Fig. 1B) . MAGP1B mRNA expression in the SAOS-MAGP1B line is ∼37% of the level of the MAGP1A mRNA in the SAOS-MAGP1A cells.
Evidence that the transfectants express the appropriate MAGP1 protein and not just their mRNAs can be seen in the results of immunofluorescence experiments using monoclonal antibodies against the V5 tag present in the recombinant proteins (Fig. 1C) . In SAOS-MAGP1A cells, V5 immunostaining was clearly visible in a perinuclear Golgi cap, consistent with the passage of MAGP1A through the secretory pathway (Fig. 1C, left panel) . A more diffuse fluorescence consistent with a cytoplasmic localization was observed in SAOS-MAGP1B cells (Fig. 1C, right panel) . No V5 staining was seen in SAOS-C or in untransfected SAOS-2 cells (not shown).
We conclude that MAGP1A and MAGP1B are expressed stably at the mRNA and protein levels in human SAOS-2 cells.
Complex and specific transcriptional response to MAGP1B
Biotin-labeled complementary RNA was synthesized to probe the Affymetrix U133A Human Genome oligonucleotide chip platform which contains 22,283 sets of probes. All microarray experiments were performed with two independently isolated transfected cell lines using independently prepared RNA samples to probe two individual genechips for each line to account for experimental variability. Raw hybridization data were processed to extract probe set signal intensities and detection calls. In order to isolate the MAGP1B-specific response and to eliminate non-specific alterations in gene expression due to transfection effects and protein overexpression, we first identified the statistically significant changes between SAOS-MAGP1A or SAOS-MAGP1B relative to MAGP1-C. A second subtraction analysis identified the genes up-or down-regulated only in the SAOS-MAGP1B line.
There were a total of 2253 statistically significant changes (2208 up-regulated, 45 down-regulated) in gene expression in SAOS-MAGP1B cells relative to SAOS-C, while 3388 statistically significant changes were observed in SAOS-MAGP1A cells (3281 upregulated, 107 down-regulated) relative to SAOS-C. After selection of those changes taking place uniquely in SAOS-MAGP1B relative to SAOS-C, and not in SAOS-MAGP1A, we discovered 75 changes that were statistically significant, specific for MAGP1B and above a threshold of 1.5-fold variation. Out of these, 67 genes were up-regulated, whereas the expression of 8 genes was lower in SAOS-MAGP1B than in SAOS-C.
The statistically significant changes in biochemical and cellular pathways in response to over-expression of MAGP1B according to EASE analysis are summarized in Table 2 , arranged into 11 categories together with the peak ratio. Excluding the "Uncharacterized gene product" category (14 genes), the broad categories "Metabolism" (10 genes), "Gene expression" (9 genes), "Signal transduction" (8 genes), and "Development" and "Intracellular Structure" (7 genes each), comprise the bulk of the up-regulated genes. The much smaller number of down-regulated genes (8 genes) was classified into 7 categories.
The highest up-regulation was found for CSPG2, encoding the chondroitin sulfate proteoglycan, versican (peak ratio 2.76); whereas the most significant down-regulation was observed for CSTF2, Cleavage stimulation factor, subunit 2 (peak ratio 0.55), one of the factors required for 3 -end cleavage of mammalian pre-mRNAs (Takagaki, MacDonald, Shenk, & Manley, 1992) .
Validation of the genechip results by real-time PCR
Validation of the microarray results by real-time PCR of selected genes is shown in Fig. 2 . As sources of RNA we used a set of transfected SAOS-2 cells generated independently of the cell lines used in the genechip experiments in order to provide a more robust analysis. We chose the four genes uniquely induced by MAGP1B with the highest peak ratios: CSPG2 (peak ratio 2.76), CDC42EP3 (peak ratio 2.43), ITGA4 (peak ratio 2.15), and PTCH (peak ratio 2.00). Real-time PCR data were processed according to the C t value method (Livak & Schmittgen, 2001) , and normalized for equal amounts of initial RNA by amplification of 18S rRNA. Since microarray analysis may not always be able to distinguish among alternatively spliced forms of a particular gene, the detected signal may actually represent the sum of the relative contributions of all the variants. In our case, the mRNA for CSPG2 (versican) is alternatively spliced into four variants (termed V0, V1, V2, and V3) (Wight, 2002) . In order to validate the up-regulation of versican we designed isoform-specific primers to estimate the levels of induction of each splice form ( Fig. 2A) . For the remaining genes, one single set of primers was used after optimization of real-time PCR parameters. Independent real-time RT-PCR assays were performed in triplicate, and the means ± S.E.M. of the relative expression levels are shown in Fig. 2 . In all cases the up-regulation of the target genes is specific for SAOS-MAGP1B as indicated by the statistically significant (multiple t-test, p < 0.05) differences between the average expression values in SAOS-MAGP1B cells relative to the SAOS-C line (Fig. 2) . The expression values of the selected genes were in close agreement with the microarray values (Table 2) , confirming the transcriptional profile obtained by the genechip analysis.
Discussion
The function of the intracellular MAGP1B splice variant is essentially unknown, besides the fact that its transient expression in rat lung fibroblasts induced changes in cell shape and reduced adhesion to the substrate (Segade et al., 2002) . To gain insights into MAGP1B we developed transfected cell lines derived Genes with differentially changed expression in SAOS-MAGP1B cells when compared with SAOS-MAGP1A and SAOS-C cells sorted into the up-regulated or down-regulated categories. In the table, gene ontology category, gene name, gene symbol (or gene ID), the accession number and peak ratio are provided. Genes with a ≥1.5-fold change were considered as differentially regulated using human U133A oligonucleotide arrays.
form the human osteosarcoma cell line, SAOS-2. The choice of the host cell line was relatively straightforward based on (i) absence of MAGP1 expression in native SAOS-2 cells; (ii) since SAOS-2 cells deposit an extensive ECM (McQuillan, Richardson, & Bateman, 1995) they must possess the molecular machinery for posttranslational modification, secretion, and deposition of ECM proteins; and (iii) some of the major components of the SAOS-2 ECM (e.g. decorin) (McQuillan et al., 1995) are relevant to MAGP1 biology (Trask et al., 2000) . Stress responses in cells that over-express exogenous gene products may confound the gene profiling analysis if they cannot be separated from the genuine effect of MAGP1B. To minimize the problem we followed a three-pronged approach. First, all the RNA sources for gene profiling and validation were G418-selected transfected cells and no untransfected SAOS-2 cells were used. It is a reasonable assumption that any transfectioninduced stress would be similar in the three derived lines. Second, a generalized stress response to over-expression of heterologous proteins is expected to be qualitatively similar in the three lines. This is due to the fact that all lines, including SAOS-C transfected with the empty vector, over-express at least the Neomycin Resistance (neo) gene product required for G418 selection. Third, gene changes that were quantitatively similar in both SAOS-MAGP1A and SAOS-MAGP1B were subtracted from the results in order to identify genes uniquely altered in the SAOS-MAGP1B line. In this manner we are confident that our results only show the real biological effects of MAGP1B.
The analysis of the genechip results showed that the gene with the highest fold increase is CSPG2, encoding the chondroitin sulfate proteoglycan, versican, a component of the ECM of soft tissues (Wight, 2002) . The four versican splice forms (V0, V1, V2, and V3) differ in the number of glycosaminoglycan attachment sites that determine the functional specificities of the variants as much as their protein sequence (Wight, 2002) . Thus, V1 promotes cell growth and inhibits the expression of the proapoptotic protein Bad, whereas the V2 form diminishes cell growth and is not antiapoptotic (Sheng et al., 2005) . Versican V3 slows melanoma cell proliferation and augments cell adhesion and migration (Serra et al., 2005) . Interestingly, versican is found associated to the microfibrils through its interaction with fibrillin-1 (Isogai et al., 2002) . Versican is not simply a structural component of the elastic fibers. In smooth muscle cells, over-expression of versican V3 enhances cell adhesion, decreases cell proliferation, and up-regulates tropoelastin expression both at the mRNA level and as deposited elastin (Merrilees et al., 2002) . In fibroblasts that are genetically deficient in the formation of elastic fibers, overexpression of versican V3 reverses the impairment in elastogenesis and restores the formation of normal elastic laminae (Hinek, Braun, Liu, Wang, & Wight, 2004) . CDC42 Effector Protein 3 (CDC42EP3, also known as CEP3 or Borg2) (Hirsch, Pirone, & Burbelo, 2001; Joberty, Perlungher, & Macara, 1999) binds to the small GTPases CDC42 and TC10 that regulate cytoskeleton activity, cell adhesion and migration. The CDC42EP proteins may act downstream of CDC42/TC10 to induce actin filament assembly that leads to cell shape changes (Hirsch et al., 2001) , through their interaction with the septin GTPases (Joberty et al., 2001 ). The closely related CDC42EP5 (Borg3) causes a delay in cell spreading (Joberty et al., 1999) .
The product of the ITGA4 gene, Integrin ␣4, is mainly involved in cell adhesion. Thus, ␣4␤1 integrin and its ligand VCAM1 mediate a critical cell adhesion event for the survival of endothelial cells (Garmy-Susini et al., 2005) . But ␣4␤1 also promotes lamellipodia protrusion and is essential for the migration of progenitor cells to form the heart epicardium (Sengbusch, He, Pinco, & Yang, 2002) . Cells expressing Integrin ␣4, also known as VLA4, are resistant to apoptosis from loss of anchorage mediated by the PI3K/Akt/Bcl2 pathway (Matsunaga et al., 2003) . Interestingly, AKT1 is up-regulated by MAGP1B in our microarray data ( Table 2 ).
The biology of MAGP1, with its extra-and intracellular facets, is reminiscent of the extracellular components known as matricellular proteins. These are proteins that interact with cell-surface receptors, ECM, growth factors, and/or proteases, but do not themselves serve strictly or exclusively structural roles (Bornstein & Sage, 2002) . Among the better-known matricellular proteins are SPARC, thrombospondin, tenascin C, tenascin X, syndecans, and osteopontin (Bornstein & Sage, 2002) . Like SPARC, MAGP1, through its secreted MAGP1A variant, interacts with a number of ECM components (e.g. fibrillin, elastin, collagen IV, and decorin) but it is not itself a structural element of the microfibril. On the other hand, MAGP1 shows important differences with the matricellular proteins. Matricellular proteins act extracellularly to modulate cell-cell and cell-matrix interactions. However, MAGP1 expresses a strictly intracellular form, MAGP1B. This suggests instead that MAGP1 is functionally closer to a heterogeneous collection of molecules known as intracrine mediators that function inside the cell after internalization or through retention in their cells of synthesis (Re & Cook, 2006) . Intracrins are structurally heterogeneous, mainly growth regulatory, related to angiogenesis, sometimes located to the nucleus, and synthesized as multiple isoforms (Re & Cook, 2006) . A recent review on intracrins (Re & Cook, 2006) does not include extracellular matrix components, but while an intracellular role by a microfibril-associated protein is unusual, there are interesting and important precedents for matrix proteins that also function inside the cell. Lysyl oxidase is a secreted, extracellular protein that catalyzes the formation of covalent crosslinks in collagen and elastin. An enzymatically active form has been detected in the nucleus of rat vascular smooth muscle cells, where it acts as a suppressor of transformation by the Ras gene product (Kenyon et al., 1991; Nellaiappan, Risitano, Liu, Nicklas, & Kagan, 2000) .
Since the number of genes in the genome is limited, alternative splicing provides a mechanism to increase the diversity of the proteome together with a more flexible and complex regulation of cell processes. Alternatively spliced transcripts are prevalent among genes that code for extracellular matrix proteins, since many of the large structural proteins are formed by combinations of discrete structural domains present in a variable number of copies (Boyd, Pierce, Schwarzbauer, Doege, & Sandell, 1993) . The multiple splice forms of fibronectin (Schwarzbauer, 1991) , latent TGF␤-binding proteins (Oklu & Hesketh, 2000) , and laminins (Tunggal, Smyth, Paulsson, & Ott, 2000) are well-characterized examples of how isoforms differ in their functions. Moreover, alternative splicing is an efficient process to generate dual-role proteins through the inclusion or exclusion of exon modules that results in changes in localization or function (Stamm et al., 2005) . We envision a regulatory mechanism which, by controlling the ratio of splicing between MAGP1A and MAGP1B, links ECM deposition, in which extracellular MAGP1A participates, with cellular processes that prime the cell for ECM assembly through the MAGP1B-responsive genes.
In this view, MAGP1B represents a unique form of matricellular protein, one whose function is entirely carried out within the cell, although "derived" from an ECM protein. Taken together, our data uncovered a critical role of MAGP1B that should contribute towards the elucidation of the regulation of ECM assembly.
